Table 4.

Major results of health economic assessment of SBRT in the treatment of HCC

Included research	Intervention technique	Control technique	Incremental cost	Incremental output	ICER	Payment threshold	Basic conclusion
Hayeon Kim [17]	SBRTc	RFAd	8202	0.050	164,660	100,000a	Not cost-effective
Leung [18]	Sorafenib	SBRT	969,041	0.260	3788,238	2213,145b	Not cost-effective
Pollom [19]	SBRT–SBRT	RFA-SBRT	4269	0.008	558,679	100,000a	Not cost-effective
	SBRT–RFA	RFA–SBRT	4,394	0.002	2197,000	100,000a	Not cost-effective
	RFA–RFA	RFA–SBRT	283	− 0.012	–	100,000a	Dominated
Leung [20]	Proton beam therapy	SBRT	557,907	2.610	213,354	2157,024b	Cost-effective
Parikh [21]	SBRT	RFA	− 1967	− 0.035	56,301	100,000a	Not cost-effective

^a The cost unit of incremental cost, ICER, and threshold value were in US dollars; ^b The cost unit of incremental cost, ICER, and threshold value were in New Taiwan dollars; ^c stereotactic body radiotherapy; ^d radiofrequency ablation; % ICER per life-year gained, not quality life-year gained